Lead
Dexcom has announced that its new Dexcom Flex continuous glucose monitoring (CGM) system will be available in Germany in the coming weeks, targeting individuals with type 2 diabetes who use basal insulin, oral medications or GLP‑1 receptor agonists.
Background
Continuous glucose monitoring has traditionally been associated with type 1 diabetes management. Recent advances have expanded CGM use to type 2 patients, particularly those on basal insulin or newer drug classes such as GLP‑1 receptor agonists, which require careful glucose tracking to optimise dosing and avoid hypoglycaemia.
What Happened
According to a City A.M. report, Dexcom Flex provides real‑time glucose readings, personalised behavioural insights and simplified tracking tools. The system is positioned as a decision‑support platform that helps users make informed choices about diet, activity and medication adjustments.
Market & Industry Implications
The introduction of Dexcom Flex in Germany adds a CGM option specifically marketed to the large and growing population of type 2 diabetes patients on basal insulin or GLP‑1 therapy. By bundling real‑time data with behavioural analytics, Dexcom aims to differentiate its offering from existing CGM products that focus primarily on type 1 diabetes. The launch may encourage broader insurer coverage for CGM use in type 2 diabetes, potentially expanding the market size in Europe.
What to Watch
- Regulatory approval timelines and reimbursement decisions by German health insurers.
- Adoption rates among German clinicians treating type 2 diabetes with basal insulin or GLP‑1 agonists.
- Potential rollout to other European markets following the German launch.
